Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Fulcrum Therapeutics (Nasdaq: FULC) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 10:30 a.m. ET / 7:30 a.m. PT.
A live webcast will be accessible via Fulcrum's Events and Presentations page and a replay will be available on the company's website for at least 30 days following the presentation.
Details
News Market Reaction – FULC
On Jan 7, the day this news came out, FULC closed 0.10% below the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Conference date
- January 14, 2026
- Presentation date at 44th Annual J.P. Morgan Healthcare Conference
- Presentation time (ET)
- 10:30 a.m. ET
- Scheduled start time for management presentation
- Presentation time (PT)
- 7:30 a.m. PT
- Local time for San Francisco conference presentation
- Webcast replay period
- 30 days
- Replay availability on company website after presentation
Historical Context
-
Upsized $175M stock and pre-funded warrant offering under effective registration.
-
Proposed $150M common stock offering with $22.5M underwriter option.
-
Positive Phase 1b PIONEER pociredir data in sickle cell disease at ASH.
-
Nasdaq Rule 5635(c)(4) stock option grant to a new employee.
-
Scheduled investor event to review new PIONEER trial clinical data.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT.
A live webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.